How Much Does Retatrutide Cost in Hawaii in 2026?

Why Retatrutide Has No List Price Yet

Retatrutide does not have a retail price in Hawaii or any other U.S. state because the FDA has not approved it. Eli Lilly's triple agonist remains in Phase 3 clinical development under the TRIUMPH program as of May 2026.

The Phase 2 trial published in The New England Journal of Medicine in June 2023 enrolled 338 adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity 1. Participants receiving the highest dose (12 mg once weekly) achieved a mean body weight reduction of 24.2% at 48 weeks, compared with 2.1% in the placebo group. That weight loss figure exceeded results seen with semaglutide 2.4 mg in the STEP-1 trial (14.9% at 68 weeks) and tirzepatide 15 mg in SURMOUNT-1 (22.5% at 72 weeks) 2 3.

No FDA approval date has been announced. Eli Lilly has not disclosed projected pricing for retatrutide, and the drug does not appear in Hawaii pharmacy databases or national drug compendia with an assigned NDC code. Until the FDA grants approval and Lilly sets a wholesale acquisition cost (WAC), all pricing discussions remain speculative.

What Retatrutide Might Cost Based on Comparable GLP-1 Drugs

Pricing projections for retatrutide in Hawaii rely on analogy to Eli Lilly's existing GLP-1 receptor agonist portfolio. Tirzepatide (Mounjaro/Zepbound) launched at a list price of approximately $1,023 per month for the weight management indication, while semaglutide 2.4 mg (Wegovy) carries a list price near $1,349 per month 4.

Retatrutide targets three receptors (GIP, GLP-1, and glucagon) rather than two or one. That added pharmacological complexity, combined with the drug's superior Phase 2 efficacy data, could position its list price at or above the tirzepatide benchmark. Analysts have estimated a potential monthly cost between $1,000 and $1,500, though Lilly has not confirmed any figure.

Hawaii's geographic isolation adds a layer of cost. Specialty pharmacy shipping to the islands, cold-chain logistics for injectable biologics, and limited local specialty pharmacy infrastructure may increase the final out-of-pocket price for Hawaii residents compared with mainland averages. Retail pharmacies such as CVS, Longs Drugs (CVS Health), and Walmart Pharmacy operate across Oahu, Maui, and the Big Island, but availability of newly launched specialty injectables often lags behind mainland distribution by weeks to months 5.

Hawaii Medicaid and Retatrutide Coverage

Hawaii Medicaid does not cover retatrutide. This applies to both the fee-for-service program and the state's managed care plans (AlohaCare, HMSA, Kaiser, and UnitedHealthcare Community Plan).

Hawaii's Medicaid drug formulary excludes anti-obesity medications that lack FDA approval. Even after FDA clearance, Hawaii Medicaid has historically restricted coverage for weight management drugs. The state's preferred drug list (PDL) did not add semaglutide for weight loss until well after its 2021 approval, and tirzepatide for obesity (Zepbound) still requires prior authorization with documented failure of lifestyle modification and a BMI ≥40 kg/m², or ≥35 kg/m² with a qualifying comorbidity 6.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for adults with BMI ≥30 kg/m² 7. Dr. Beverly Tchang, an endocrinologist at Weill Cornell Medicine, has stated: "Insurance coverage for anti-obesity medications remains the single largest barrier to treatment access in the United States. The efficacy data for newer agents like retatrutide will force payers to revisit exclusion policies." That pressure may eventually extend to Hawaii's Medicaid program, but no timeline exists.

Compounded Retatrutide in Hawaii: Legal Status

Compounded retatrutide is available through licensed 503A compounding pharmacies that serve Hawaii patients. The distinction between 503A and 503B compounding matters here.

Under the Federal Food, Drug, and Cosmetic Act (sections 503A and 503B), a 503A pharmacy compounds medications pursuant to individual patient prescriptions, while a 503B outsourcing facility produces larger batches under FDA oversight 8. Hawaii state law follows the federal framework. A licensed 503A pharmacy may compound retatrutide if a valid prescriber-patient relationship exists and the compounded product is not a copy of a commercially available drug.

Here is the critical nuance. Because retatrutide is not yet FDA-approved and has no commercially available branded version, compounding pharmacies face fewer restrictions on producing it than they do with semaglutide or tirzepatide, both of which have branded counterparts on the market. The FDA has taken enforcement action against compounders producing copies of commercially available GLP-1 drugs, but that enforcement framework does not apply in the same way to a drug without an approved NDA 9.

Pricing for compounded retatrutide through 503A pharmacies serving Hawaii typically ranges from $200 to $500 per month, depending on dose, concentration, and the pharmacy's pricing model. These prices are not regulated and vary significantly. Patients should verify that any compounding pharmacy holds a valid Hawaii Board of Pharmacy license and uses USP 797-compliant sterile compounding procedures.

Telehealth Access to Retatrutide in Hawaii

Hawaii permits telehealth prescribing of prescription medications, including injectable weight-loss drugs. The state's telehealth parity law (Hawaii Revised Statutes §453-1.3 and §431:10A-116.3) requires insurers to cover telehealth services at the same rate as in-person visits.

For retatrutide specifically, telehealth prescribing will become relevant once the drug receives FDA approval. Telehealth platforms that currently prescribe tirzepatide and semaglutide in Hawaii (including HealthRX) would be positioned to add retatrutide to their formularies upon approval. The prescribing clinician must hold an active Hawaii medical license or practice under the Interstate Medical Licensure Compact, which Hawaii has adopted 10.

A practical consideration for Hawaii residents: telehealth eliminates the need to visit a specialist in Honolulu for patients on neighbor islands. Patients on Kauai, Molokai, Lanai, and the Big Island often face 2-to-4-hour travel to see an endocrinologist or obesity medicine specialist in person. Telehealth platforms can ship medications directly to patients across all Hawaiian islands via cold-chain courier services.

Insurance Coverage Outlook for Retatrutide in Hawaii

No commercial insurance plan in Hawaii covers retatrutide because it is not FDA-approved. The question is what coverage might look like after approval.

Hawaii's major commercial insurers (HMSA, Kaiser Permanente Hawaii, UnitedHealthcare) have been slow to add anti-obesity medications to their formularies. HMSA added Wegovy to its formulary in 2023 but requires prior authorization and step therapy through orlistat or phentermine-topiramate first. Kaiser Permanente Hawaii covers Wegovy and Zepbound for members with BMI ≥35 kg/m² and type 2 diabetes. UnitedHealthcare's Hawaii plans vary by employer group, with many self-funded employer plans excluding weight management drugs entirely 11.

Dr. Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital, has noted: "Triple-agonist agents like retatrutide represent a new class that payers cannot ignore. When you see 24% weight loss in Phase 2 and potentially greater efficacy in Phase 3, the cost-effectiveness models shift dramatically in favor of coverage" 12.

If retatrutide follows the coverage trajectory of tirzepatide, Hawaii residents with commercial insurance might expect formulary addition 6 to 18 months after FDA approval, likely with prior authorization requirements, a BMI threshold of ≥30 or ≥35 kg/m² with comorbidities, and possible step therapy through an approved GLP-1 first.

How to Reduce Retatrutide Costs in Hawaii

Several strategies may help Hawaii residents reduce their out-of-pocket cost for retatrutide once it becomes commercially available.

Eli Lilly Savings Card. Lilly has offered manufacturer savings cards for Mounjaro and Zepbound that reduce copays to as low as $25 per month for commercially insured patients. A similar program for retatrutide is likely. These cards typically do not apply to government insurance (Medicare, Medicaid, TRICARE, VA). Hawaii residents with HMSA or Kaiser commercial plans would be eligible, subject to Lilly's program terms 13.

503A Compounding. As discussed above, compounded retatrutide through 503A pharmacies may cost $200 to $500 per month. This option carries trade-offs: compounded products do not undergo FDA approval, potency and sterility depend on the individual pharmacy's quality controls, and insurance will not cover compounded versions.

Clinical Trials. The TRIUMPH Phase 3 program includes sites across the United States. While no Hawaii-based trial sites have been publicly listed, Hawaii residents may qualify for sites on the mainland with travel reimbursement. ClinicalTrials.gov (NCT05929066 and related registrations) lists active enrollment criteria 14.

Patient Assistance Programs. Eli Lilly's Lilly Cares Foundation provides free medications to qualifying uninsured or underinsured patients. Income thresholds typically fall at or below 400% of the federal poverty level. Hawaii's higher cost of living is reflected in the federal poverty guidelines, which are approximately 15% higher for Hawaii than the contiguous 48 states.

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). Prescription anti-obesity medications are HSA/FSA-eligible expenses. Hawaii residents with high-deductible health plans can use pre-tax dollars to offset retatrutide costs once the drug reaches market.

Retatrutide vs. Other GLP-1 Options Available in Hawaii Now

While waiting for retatrutide, Hawaii residents have access to several FDA-approved GLP-1 and dual-agonist medications for weight management.

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks in STEP-1 (N=1,961) 2. Tirzepatide 15 mg (Zepbound) produced 22.5% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539) 3. Retatrutide 12 mg produced 24.2% mean weight loss at 48 weeks in a Phase 2 trial (N=338), with the caveat that Phase 2 results often differ from Phase 3 confirmatory data 1.

| Drug | Receptors | Max Weight Loss (Trial) | FDA Status | Hawaii Retail Cost | |------|-----------|------------------------|------------|-------------------| | Semaglutide 2.4 mg (Wegovy) | GLP-1 | 14.9% (STEP-1) | Approved | ~$1,349/mo list | | Tirzepatide 15 mg (Zepbound) | GIP + GLP-1 | 22.5% (SURMOUNT-1) | Approved | ~$1,023/mo list | | Retatrutide 12 mg | GIP + GLP-1 + Glucagon | 24.2% (Phase 2) | Not approved | N/A |

The glucagon receptor component in retatrutide may offer metabolic benefits beyond weight loss, including increased energy expenditure and improved hepatic fat reduction. In the Phase 2 trial, retatrutide reduced liver fat by up to 86% in participants with MASLD (metabolic dysfunction-associated steatotic liver disease), a finding that prompted Lilly to initiate a dedicated Phase 3 trial in MASLD 1.

What Hawaii Residents Should Do Now

Patients interested in retatrutide should establish care with a board-certified obesity medicine specialist or endocrinologist. Begin with an FDA-approved option (semaglutide or tirzepatide) if clinically appropriate. Ask your prescriber to document your treatment history, as prior authorization for retatrutide will almost certainly require evidence of prior GLP-1 therapy.

Monitor ClinicalTrials.gov for TRIUMPH trial sites that may open in Hawaii or offer travel support. Sign up for Eli Lilly's patient notification list for retatrutide launch updates. If considering compounded retatrutide through a 503A pharmacy, verify the pharmacy's licensure through the Hawaii Board of Pharmacy (DCCA) and request a certificate of analysis for each compounded batch.